Universal Rapid Human Immunodeficiency Virus Screening at Delivery: A Cost-Effectiveness Analysis

Table 6

Univariate sensitivity analysis of universal rapid HIV screening relative to standard of care II.

Variable	Detected range	Estimated incremental cost ($)	Estimated incremental QALY (10^−5)	Incremental cost-effectiveness ratio ($/QALY)
QALY saved per prevention of 1 case of MTCT	5~25	26,968.76	1.97~9.83	13,720.22~2,744.04
Estimated lifetime medical cost of PAH	$250k~550k	53,759.00~(−64,178.29)	7.47	7,197.27~(−8,592.20)
HIV prevalence	0.5%~10%	27,353.64~24,741.98	7.58~6.85	3,610.58~3,610.58
HIV annual cumulative incidence	0.01%~0.15%	136,311.47~(−62,625.81)	0.86~12.89	158,710.06~(−4,860.01)
Cost of rapid test	$11.90~$16.32	(−2,660.25)~39,859.31	7.47	(−356.16)~5,336.37
Cost of neonatal prophylaxis	$185~$210	26,968.76~27,267.68	7.47	3,610.58~3,650.60